Crucell
 |
|
| Type | Privately held naamloze vennootschap; subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2000 |
| Headquarters | Leiden, Netherlands |
| Key people | Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board) |
| Products | Vaccines and antibodies |
| Revenue | €329.8 million (2010)[1] |
| Operating income |  (€34.3 million) (2010)[1] |
| Profit | (€27.6 million) (2010)[1] |
| Total assets | €967.1 million (end 2010)[1] |
| Total equity | €786.4 million (end 2010)[1] |
| Owner(s) | Johnson & Johnson |
| Employees | 1,250 (2009)[2] |
| Website | www.crucell.com |
Crucell is a biotechnology company specializing in vaccines and antibodies. The firm, a subsidiary of Johnson & Johnson, is headquartered in Leiden, Netherlands. Crucell shares were previously listed on the Euronext Amsterdam exchange and formed part of the AMX index until April 2011, when J&J completed a tender offer for the company.
Contents |
[edit] History
In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.
In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.
On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.
On 28 September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[3] This follows in the wake of Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J agreed to acquire the rest of the company in October 2010, taking its stake to over 95% by February 2011[4] and delisting the company from stock exchanges two months later.[5]
[edit] Vaccine products
[edit] Paediatric
- Quinvaxem
- Hepavax-Gene
- MoRu-Viraten
- Epaxal-Junior
[edit] Travel and endemic
- Epaxal
- Vivotif
- Dukoral
[edit] Respiratory
- Inflexal V
[edit] References
- ^ a b c d e "Annual Results 2010". Crucell. http://hugin.info/132631/R/1485773/420938.pdf. Retrieved 27 February 2011.
- ^ "Annual Report 2009". Crucell. http://crucell.com/annual_report_2009/pdfs/Crucell_AR09_Complete.pdf. Retrieved 2010-05-23.
- ^ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. http://www.reuters.com/article/rbssPharmaceuticals%20-%20Generic%20&%20Specialty/idUSLS21205620090928. Retrieved 28 September 2009.
- ^ Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. http://online.wsj.com/article/BT-CO-20110217-717650.html. Retrieved 27 February 2011.
- ^ Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. http://www.reuters.com/article/2011/04/11/crucell-idUSLDE73A0FR20110411. Retrieved 16 April 2011.
[edit] External links
|
||||||||||||||
4.3% ( |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
